A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Alloimmune ThrombocytopeniaFetal Alloimmune Thrombocytopenia
Interventions
DRUG

IVIG (Intravenous Immunoglobulin)

one gram per kg of IVIG per infusion given either once or twice

DRUG

prednisone

in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day

Trial Locations (1)

10021

New York Presbyterian Hospital-Weill Cornell Medical Center, New York

All Listed Sponsors
collaborator

New York Presbyterian Hospital

OTHER

collaborator

Columbia University

OTHER

lead

Weill Medical College of Cornell University

OTHER

NCT00194987 - A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia | Biotech Hunter | Biotech Hunter